Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 14

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 14
---
 prospectus will go           
 to the selling shareholder. However, we may receive the proceeds from the exercise of any January 2024 PIPE Warrants if the selling        
 shareholders do not exercise the January 2024 PIPE Warrants on a cashless basis, if and when exercised. See the section of this prospectus 
 titled “Use of Proceeds.”                                                                                                                  |
| Risk factors                                                                                                  |     | Investing in our securities involves a high degree                                                                                         
 of risk. You should read the “Risk Factors” section starting on page 5 of this prospectus and “Item 3. - Key                               
 Information – D. Risk Factors” in our annual report on Form 20-F for the year ended October 31, 2024, or the 2024 Annual                   
 Report, incorporated by reference herein, and other information included or incorporated by reference in this prospectus for a discussion  
 of factors to consider carefully before deciding to invest in our common shares.                                                           |
| Nasdaq Capital Market symbol                                                                                  |     | “CMND”                                                                                                                                     |
| Frankfurt Stock Exchange symbol                                                                               |     | “CWY”                                                                                                                                      |

Unless otherwise stated, all information in this prospectus is based on 5,466,441 common shares outstanding as of September 12, 2025, and does not include the following as of that date:

| ● | 2,238,848 common shares issuable upon the exercise of warrants outstanding as of such date, at exercise prices ranging from $1.0777 to $243.75, all of which were vested as of such date; |
| ● | 5,521 common shares issuable upon the exercise of                                                                                                                                         
 options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average                                                        
 exercise price of $434.63, of which 5,509 were vested as of such date; and                                                                                                                |
| ● | 1,251 common shares issuable upon the exercise of restricted share units issued to consultants under consulting agreements.                                                               |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to no exercise of the warrants or options described above See “Description of Share Capital” for additional information.

<div align='center'>4

RISK FACTORS</div>

You should carefully consider the risks described below and the risks described in our 2024 Annual Report which are incorporated by reference herein, as well as the financial or other information included in this prospectus or incorporated by reference in this prospectus